Name | RWJ-51204 |
Synonyms | RWJ-51204 Pyrido[1,2-a]benzimidazole-4-carboxamide, 5-(ethoxymethyl)-7-fluoro-N-(2-fluorophenyl)-1,2,3,5-tetrahydro-3-oxo- |
CAS | 205701-85-5 |
Molecular Formula | C21H19F2N3O3 |
Molar Mass | 399.39 |
Density | 1.41±0.1 g/cm3(Predicted) |
Boling Point | 533.0±50.0 °C(Predicted) |
Solubility | DMSO |
pKa | 10.81±0.70(Predicted) |
Storage Condition | -20℃ |
In vitro study | RWJ-51204 binds to receptors in the cerebral cortex, cerebellum, or medulla-spinal cord with K i ranging from 0.2 to 0.6 nM. |
In vivo study | RWJ-51204 is orally active in anxiolytic efficacy tests. WJ 51204 dose-relatedly antagonizes PTZ-induced clonic convulsions when administered orally (ED 50 = 0.04 mg/kg). RWJ-51204 is effective in the conflict test in monkeys (ED 50 of approximately 0.5 mg/kg p.o.). RWJ-51204 potently impairs rotarod performance in rats (ED 50 = 0.12 mg/kg), and all rats given RWJ-51204 orally at 30 mg/kg exhibit sedation, reduced skeletal muscle tone, and impairment of rotarod performance. |